Annals of surgery · 2024
Trends in the Management and Outcomes of Neuroendocrine Liver Metastases: A 3-decade, Multicenter Observational Cohort Study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Frilling Andrea, Clift Ashley K, Kaemmerer Daniel, Steinkraus Kira C, Schrader Joerg, Wolter Stefan, Drymousis Panagiotis, Liedke Marc-Olaf, Hommann Merten, Habib Nagy, Baum Richard P, Wasan Harpreet, Modlin Irvin M, Izbicki Jakob R
Аннотация
OBJECTIVE: To describe the evolution of management strategies for neuroendocrine liver metastases (NE LM) and trends in patient outcomes over the preceding 3 decades.
BACKGROUND: Liver metastases are common in neuroendocrine neoplasms and impair prognosis. A broad therapeutic armamentarium has evolved over recent decades, but there remains uncertainty regarding optimal treatment selection and sequencing.
METHODS: Retrospective cohort study pooling data from 4 specialist centers of excellence in the United Kingdom and Germany for individuals diagnosed with neuroendocrine liver metastases between January 1, 1990, and December 31, 2020. We explored trends in theranostic strategies over 3 decades and quantified overall survival (cohort, and by decade-defined temporal periods).
RESULTS: We identified 551 individuals with NE LM with a median age at diagnosis of 59.1 years; 453 (82.2%) had synchronous metastases, and 402 (73.0%) underwent multimodal therapy. In all centers, somatostatin receptor-based PET/CT and MRI were the preferred imaging techniques. There were significant trends in the use of somatostatin analogs and peptide receptor radionuclide therapy, but the number of surgical resections remained stable. Overall survival (OS) at 5 and 10 years was 77.5% and 58.1%, respectively. Across the 3 time periods, 5-year OS significantly improved-period I: 45.2%, period II: 66.0%, and period III: 75.7%. Ten-year OS showed overlapping confidence intervals for period I (23.5%) and period II (18.3%) but doubled in period III (55.5%). On multivariable analysis, the use of multimodal therapy strategies was significantly associated with improved overall survival (HR=0.59, 95% CI: 0.40-0.88, P =0.009).
CONCLUSIONS: Improved imaging modalities and modifications in specific therapies as components of multimodal treatment concepts are concordant with significantly improved survival outcomes in NELM over 30 years. The use of multimodal therapy improved overall survival in patients with NE LM. Future studies should determine optimal treatment selection and sequencing and the role of novel biomarkers to guide these.
BACKGROUND: Liver metastases are common in neuroendocrine neoplasms and impair prognosis. A broad therapeutic armamentarium has evolved over recent decades, but there remains uncertainty regarding optimal treatment selection and sequencing.
METHODS: Retrospective cohort study pooling data from 4 specialist centers of excellence in the United Kingdom and Germany for individuals diagnosed with neuroendocrine liver metastases between January 1, 1990, and December 31, 2020. We explored trends in theranostic strategies over 3 decades and quantified overall survival (cohort, and by decade-defined temporal periods).
RESULTS: We identified 551 individuals with NE LM with a median age at diagnosis of 59.1 years; 453 (82.2%) had synchronous metastases, and 402 (73.0%) underwent multimodal therapy. In all centers, somatostatin receptor-based PET/CT and MRI were the preferred imaging techniques. There were significant trends in the use of somatostatin analogs and peptide receptor radionuclide therapy, but the number of surgical resections remained stable. Overall survival (OS) at 5 and 10 years was 77.5% and 58.1%, respectively. Across the 3 time periods, 5-year OS significantly improved-period I: 45.2%, period II: 66.0%, and period III: 75.7%. Ten-year OS showed overlapping confidence intervals for period I (23.5%) and period II (18.3%) but doubled in period III (55.5%). On multivariable analysis, the use of multimodal therapy strategies was significantly associated with improved overall survival (HR=0.59, 95% CI: 0.40-0.88, P =0.009).
CONCLUSIONS: Improved imaging modalities and modifications in specific therapies as components of multimodal treatment concepts are concordant with significantly improved survival outcomes in NELM over 30 years. The use of multimodal therapy improved overall survival in patients with NE LM. Future studies should determine optimal treatment selection and sequencing and the role of novel biomarkers to guide these.